Professor after ESSM: "The interest in Dicot Pharma's work continues to grow

The pharmaceutical company Dicot Pharma was invited to present its clinical studies at ESSM, the leading European conference in sexual medicine, organized by the European Society for Sexual Medicine. The recurring conference, which this year took place on February 20-22 in Vienna, brings together the foremost experts in the field and serves as a central platform for the latest research findings and innovations.

Dicot Pharma was represented by its CSO Charlotta Gauffin and Professor François Giuliano, a urologist and specialist in male sexual health and former President of ESSM. Professor Giuliano gave a podium presentation of the results from the company's phase 1 clinical trial and the design of the ongoing phase 2a trial, in which he is involved as a medical expert.

- I can see that the awareness of and interest in Dicot Pharma's work continues to grow in the community of sexual medicine. During the conference, several leading experts within the field have showed interest, asked questions, and expressed their enthusiasm," comments Professor Giuliano.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 8,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.